Egetis (Q3 review) - Focus on US application
Redeye returns with an updated view of Egetis Therapeutics following the Q3 report and the recent ReTRIACt readout.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/